Petitjean A, et al. - In this cost-effectiveness analysis performed at specialist oncology centers in France, researchers compared bevacizumab plus paclitaxel to paclitaxel alone with respect to cost-effectiveness as the first-line treatment of HER2 (Human epidermal growth factor receptor 2)-negative metastatic breast cancer. They used a three-state Markov model and clinical input data from 3,426 HER2-negative metastatic breast cancer patients treated with bevacizumab plus paclitaxel or paclitaxel alone. Incremental gain of 0.72 life years and 0.48 quality-adjusted life years (QALYs) was offered by bevacizumab plus paclitaxel vs paclitaxel alone. Bevacizumab plus paclitaxel yielded incremental lifetime cost of EUR 27,390, resulting in an incremental cost-effectiveness ratio (ICER) of EUR 56,721 per QALY gained for bevacizumab plus paclitaxel vs paclitaxel alone. The ICER was EUR 66,874 per QALY gained in a subgroup of triple negative patients. Overall, findings highlighted possible cost-effectiveness of bevacizumab plus paclitaxel vs paclitaxel alone for the first-line treatment of HER2-negative metastatic breast cancer in specialized oncology centers in France.